Ketamine and its chemical derivative, esketamine, have the ability to alleviate severe depression almost instantly, particularly in cases resistant to other treatments. This represents a significant breakthrough in psychiatry. However, a complex mix of economic, regulatory, and research barriers have resulted in these potentially life-saving treatments remaining out of reach for many patients with severe depression.